SHR-A1811

Clinical trials for SHR-A1811 explained in plain language.

Never miss a new study

Get alerted when new SHR-A1811 trials appear

Sign up with your email to follow new studies for SHR-A1811, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo aims to boost breast cancer remission before surgery

Disease control Not yet recruiting

This study tests a new drug combination (SHR-A1811 plus pertuzumab) given before surgery to women with early or locally advanced HR-positive, HER2-positive breast cancer. The goal is to see if this approach can eliminate cancer more effectively than standard chemo, while reducing…

Matched conditions: SHR-A1811

Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control

Last updated May 26, 2026 09:54 UTC

SHR-A1811

Get alerted when new SHR-A1811 trials appear

New drug combo aims to boost breast cancer remission before surgery